Skip to main navigation

About
R&D
Pipeline
Investors & Media
Careers

Investors & Media

Overview
News
Events & Presentations
Stock Information
- Stock Quote & Chart
- Analyst Coverage
SEC Filings
Corporate Governance
Investor Resources
- FAQs
- Investor Contact

News

Year

March 17, 2020

NGM Bio Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights

March 9, 2020

Aetna Wun Trombley, Ph.D. to Step Down as President and Chief Operating Officer of NGM Bio to Assume Chief Executive Officer Role at Undisclosed Privately Held Company

February 25, 2020

NGM Bio to Present at Cowen and Company 40th Annual Health Care Conference

February 24, 2020

NGM Bio Announces Positive Preliminary Topline Liver Histology and Biomarker Data from 24-Week Phase 2 Study (Cohort 4) of Aldafermin in NASH Patients, Including Statistically Significant Achievement of Composite Endpoint of Both Fibrosis Improvement and Resolution of NASH versus Placebo

Pagination

Current page 1
Page 2
Next page
Last page

Displaying 1 - 4 of 6

Stock Quote

Contact Information

Investor Relations:
ir@ngmbio.com

Media Relations:
media@ngmbio.com

Toolkit

© 2020 NGM Biopharmaceuticals, Inc..

All Rights Reserved.

Privacy Policy.

Top